Please login to the form below

Not currently logged in
Email:
Password:

Merck halts work on pain drug

Merck & Co and Canadian-headquartered Neuromed Pharmaceuticals have stopped the development of an experimental pain drug that disappointed in clinical trials

US-based Merck & Co and Canadian-headquartered Neuromed Pharmaceuticals have stopped the development of an experimental pain drug that disappointed in clinical trials.

Neuromed said in press statement: "NMED-160 (MK-6721) did not demonstrate the ideal pharmaceutical characteristics considered necessary to advance the compound further in development."

The drug is an N-type calcium channel blocker which was designed to interfere with the transmission of pain signals. Neuromed added that itself and Merck are still trying to develop similar products.

Merck entered into the agreement with Neuromed in March 2006, which was initially worth USD 475m to the company. Since Merckís Vioxx was withdrawn from the world market, Merck has been trying to find painkillers to fill its pipeline gap for this indication.

9th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics